Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) today reported promising in vitro data for IDX320, an HCV protease inhibitor, demonstrating potent and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE